Ignite Creation Date:
2025-12-25 @ 4:01 AM
Ignite Modification Date:
2025-12-26 @ 2:54 AM
Study NCT ID:
NCT05430802
Status:
RECRUITING
Last Update Posted:
2022-06-24
First Post:
2022-06-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)
Sponsor:
Tang-Du Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-24
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-03-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-20
First Submit QC Date:
None
Study First Post Date:
2022-06-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-20
Last Update Post Date:
2022-06-24
Last Update Post Date Type:
ACTUAL